Targeted Protein Degradation Market

Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition): Distribution by Type of Protein degrader, Therapeutic Areas, Route of administration, Key Contributing Technologies and Key Geographies, 2021-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    341

  • Pages
    434

  • View Count
    35625

Targeted Protein Degradation Market Overview

The targeted protein degradation market is estimated to be worth $452 million in 2021 and is expected to grow at CAGR of 27% during the forecast period. Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule. In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.

This image provides list of Targeted Protein Degradation-based Drugs and Technology Platforms. Presently, several small molecule protein degraders are being evaluated for the treatment of a wide variety of disease indications; PROTACs is the most prominent sub-class in this segment with 8+ enabling technologies This image presents current market landscape of Targeted Protein Degradation Therapeutics. Most of the pipeline candidates are in the early phases of development, and predominantly designed to target diverse types of cancers; majority of the drug candidates are designed for administration via non-invasive routes This image describes the developer landscape of Targeted Protein Degraders. Although start-ups and mid-sized firms are spearheading the innovation in this domain, many big pharmaceutical companies have also undertaken diverse initiatives related to protein degrader-based therapies

Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in targeted protein degradation market have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy market growth during the forecast period.

Key Companies in Targeted Protein Degradation Market 

Examples of key companies engaged in protein degradation market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Radius Health, Celgene, Sanofi Genzyme, AstraZeneca, Arvinas, BioTheryX, Captor Therapeutics, C4 Therapeutics, Genentech, Hinova Pharmaceuticals, Kangpu Biopharmaceuticals, Kymera Therapeutics, Mission Therapeutics, Progenra and Zenopharm. This market report includes an easily searchable excel database of all the drug developers in the targeted protein degradation market, worldwide.

Recent Developments in Targeted Protein Degradation Market:

Several recent developments have taken place in the field of targeted protein degradation market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In September 2023, Nurix entered into a strategic collaboration with Seagen with an aim to develop a portfolio of Degrader-Antibody Conjugates (DACs) to deliver a targeted protein degrader payload to selectively kill cancer cells. 
  • In June 2023, Astellas entered into research and collaboration agreement with Cullgen in order to advance innovative targeted protein degraders. 
  • In May 2023, Cullgen raised USD 40 million in Series C funding rounds with an aim to strengthen the development of small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology.

Scope of the Report

The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition), 2021-2035: Distribution by Type of Protein degrader (degronimids, PROTACs, SARDs / SERDs, and specific BET and DUB inhibitors, and other inhibitors), Therapeutic Area (Neurological Disorders, Oncological Disorders, and Other Therapeutic Areas), Route of administration (Oral, Intravenous and Others), Key Contributing Technologies and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World)’ market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the targeted protein degradation market. The focus of this market research report is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. In addition, the market research report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in targeted protein degradation market.  

This image provides information on patents that have been filed / granted related to Targeted Protein Degradation Enabling Technologies. Over time, more than 14,500 patents related to target protein degradation technologies have been filed / granted to various industry and non-industry players, indicating the rising level of R&D activity in this field This image provides information on funding and investments received by the companies engaged in Targeted Protein Degradation Market. Foreseeing a lucrative future, private and public investors have invested over USD 5 billion, across 130+ instances, into firms involved in the development of protein degrader therapies This image provides information about completed, ongoing and planned clinical studies of Targeted Protein Degraders. Till date, more than 8,500 patients have been enrolled in clinical trials of various protein degrader-based interventions; the most advanced candidates are being developed to treat breast cancer

Amongst other elements, the market report includes:

  • A detailed review of the current market landscape of targeted protein degradation-based therapeutics, including information on type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of biological target(s), associated ubiquitin ligase(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others). In addition, it presents a list on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s). 
  • An overview of the overall landscape of target protein degradation enabling technologies, featuring an analysis based on type of degrader. In addition, it presents a list of targeted protein degradation enabling technology developers and analysis based on various parameters, such as year of establishment, company size and location of headquarters. 
  • Detailed profiles of prominent players engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each profile features a brief overview of the company, its financial information (if available), detailed description of their respective lead drug candidates, and recent developments and an informed future outlook. Additionally, each drug profile features information on the type of drug, current status of development, route of administration, target indications, and a brief summary of its developmental history. 
  • Tabulated profiles of leading industry players (shortlisted on the basis of the number of candidates in development pipeline). Each profile includes details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with information on respective drug candidates. 
  • An in-depth analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), trial focus, target therapeutic area, key indications, and clinical endpoints.
  • A detailed analysis of grants that have been awarded to various research institutes for targeted protein degradation projects, in the period between 2017 and 2020, on the basis of important parameters, such as year of award, amount awarded, administering institute center, support period, funding mechanism, type of grant application, purpose of grant award, activity code, emerging focus areas of the grants, study section, popular NIH departments, study section, and type of recipient organization, highlighting popular recipient organizations, popular program officers and regional distribution of recipient organizations.  
  • A detailed publication analysis peer-reviewed, scientific articles that have been published between 2017 and Q3 2019, highlighting the research focus within the industry. It also highlights the key trends observed across publications, including information on type of publication, year of publication, study objective, popular keywords, type of protein degrader, biological target, associated ubiquitin enzyme, number of publications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in targeted protein degradation market and impact factor of the journal). 
  • An insightful analysis of the patents filed / granted for targeted protein degradation enabling technologies, since 2018, taking into consideration various parameters, such as type of patent, publication year, geographical location, type of applicant, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. The chapter also includes a detailed patent benchmarking and an insightful valuation analysis.
  • A list of key opinion leaders (KOLs) within targeted protein degradation market, and their assessment (based on the strength and activeness) represented in the form of 2×2 matrices. The chapter also includes a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).
  • An analysis of the partnerships that have been established in targeted protein degradation market, during the period 2014-2020, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
  • An analysis of the investments in the form of seed financing, venture capital financing, debt financing, grants / awards, initial public offerings (IPOs) and subsequent offerings, made at various stages of development of the companies engaged in targeted protein degradation market.
  • A detailed deal structure analysis, highlighting cash flows and net present values of licensor and licensee, taking into consideration multiple likely scenarios of upfront, milestone and royalty payments.
This image presents the key opinion leaders of this domain. Prominent scientists / medical research professionals, who have been actively involved in clinical research related to targeted protein degraders, are presently considered key opinion leaders in this domain This image highlights the partnership activity undertaken by players engaged in Targeted Protein Degradation Market. The increasing interest in this upcoming class of therapeutics is reflected in the partnership activity worldwide; most of the recent deals were established around protein degrader-related technology platforms This image provides the information on deal structures of Targeted Protein Degradation Market. Our proprietary deal structure model suggests that IP owners should adopt a scenario-based approach to identify the most optimum / valuable deal structure while licensing their technology

The key objective of targeted protein degradation market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for targeted protein degradation market during the forecast period. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided informed estimates on the evolution of the market over the forecast period 2021-2035. For estimating the future market opportunities for technology providers, we have considered the likely licensing deal structures and agreements that are likely to be established in the foreseen future. The future opportunity within the targeted protein degradation market has been segmented across [A] different types of protein degraders (degronimids, PROTACs, SARDs / SERDs, Specific BET and DUB Inhibitors, and other inhibitors), [B] therapeutic areas (oncological disorders, neurological disorders, and other therapeutic areas), [C] route of administration (oral route, intravenous route, and other routes), and [D] key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in targeted protein degradation market. The market report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Laura Itzhaki, Founder and Chief Scientific Officer, Polyprox Therapeutics
  • Louise Bergeron, Vice President, Xios Therapeutics
  • Martin Wiles, Vice President Business Development and Licensing, Almac Discovery & Gerald Gavory, Director of Biology, Almac Discovery
  • Jason Brown, Scientific and Business Development Director, Ubiquigent
  • Anonymous, Director of Oncology Research, Large Company
  • Anonymous, Chief Scientific Officer, Very Small Company
  • Paul Wallace, Chief Business Officer, Mission Therapeutics
  • Katrin Rittinger, Research Group Leader, Francis Crick Institute
  • Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University of Delaware

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is targeted protein degradation?

Answer: Targeted protein degradation in pharmaceuticals refers to the use of protein degraders to regulate biological pathways by selectively downregulating a target protein by degrading them.

Question 2: How big is the targeted protein degradation market?

Answer: The targeted protein degradation market size is estimated to be worth $452 million in 2021.

Question 3: What is the projected market growth of the targeted protein degradation market?

Answer: The targeted protein degradation market is expected to grow at compounded annual growth rate (CAGR) of 27% during the forecast period 2021 – 2030.

Question 4: Who are the leading companies in the targeted protein degradation market?

Answer: Examples of key companies engaged in targeted protein degradation market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Radius Health, Celgene, Sanofi Genzyme, AstraZeneca, Arvinas, BioTheryX, Captor Therapeutics, C4 Therapeutics, Genentech, Hinova Pharmaceuticals, Kangpu Biopharmaceuticals, Kymera Therapeutics, Mission Therapeutics, Progenra and Zenopharm.

Question 5: How many product candidates are currently being evaluated by players engaged in the targeted protein degradation market?

Answer: Over 155 product candidates are currently being evaluated / under development by targeted protein degradation companies.

Question 6: Which region emerged as the hub for companies engaged in the targeted protein degradation market?

Answer: North America emerged as the hub for targeted protein degradation companies, with 40 companies established in the region.

Question 7: How many partnership deals have been inked between the stakeholders engaged in targeted protein degradation market?

Answer: Over 100 partnership deals have been inked between the stakeholders engaged in targeted protein degradation market, highlighting the consolidation efforts of the players in this industry.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com